Success Metrics

Clinical Success Rate
100.0%

Based on 2 completed trials

Completion Rate
100%(2/2)
Active Trials
2(40%)
Results Posted
50%(1 trials)

Phase Distribution

Ph phase_1
1
20%
Ph phase_3
2
40%
Ph phase_2
1
20%
Ph phase_4
1
20%

Phase Distribution

1

Early Stage

1

Mid Stage

3

Late Stage

Phase Distribution5 total trials
Phase 1Safety & dosage
1(20.0%)
Phase 2Efficacy & side effects
1(20.0%)
Phase 3Large-scale testing
2(40.0%)
Phase 4Post-market surveillance
1(20.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

66.7%

2 of 3 finished

Non-Completion Rate

33.3%

1 ended early

Currently Active

2

trials recruiting

Total Trials

5

all time

Status Distribution
Active(2)
Completed(2)
Terminated(1)

Detailed Status

Recruiting2
Completed2
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
2
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 11 (20.0%)
Phase 21 (20.0%)
Phase 32 (40.0%)
Phase 41 (20.0%)

Trials by Status

recruiting240%
withdrawn120%
completed240%

Recent Activity

2 active trials
Showing 5 of 5
recruitingphase_2

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Meropenem-Vaborbactam in Children With Complicated Urinary Tract Infection, Including Acute Pyelonephritis

NCT06672978
recruitingphase_4

Optimising TREATment for Severe Gram-Negative Bacterial Infections

NCT07004049
withdrawnphase_3

A Study of Meropenem-Vaborbactam Versus Piperacillin/Tazobactam in Participants With Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia

NCT03006679
completedphase_1

Evaluate Effects of Meropenem-Vaborbactam on QT/QTc in Healthy Volunteers

NCT03564158
completedphase_3

Efficacy/Safety of Meropenem-Vaborbactam Compared to Piperacillin-Tazobactam in Adults With cUTI and AP

NCT02166476

Clinical Trials (5)

Showing 5 of 5 trials
NCT06672978Phase 2

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Meropenem-Vaborbactam in Children With Complicated Urinary Tract Infection, Including Acute Pyelonephritis

Recruiting
NCT07004049Phase 4

Optimising TREATment for Severe Gram-Negative Bacterial Infections

Recruiting
NCT03006679Phase 3

A Study of Meropenem-Vaborbactam Versus Piperacillin/Tazobactam in Participants With Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia

Withdrawn
NCT03564158Phase 1

Evaluate Effects of Meropenem-Vaborbactam on QT/QTc in Healthy Volunteers

Completed
NCT02166476Phase 3

Efficacy/Safety of Meropenem-Vaborbactam Compared to Piperacillin-Tazobactam in Adults With cUTI and AP

Completed

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5